Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $3.779 million which beat the analyst consensus estimate of $1.033 million by 265.83 percent. This is a 203.29 percent increase over sales of $1.246 million the same period last year.
Lineage Cell Therapeutics Q3 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $3.779M Beat $1.033M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated